Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. (2023)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1182/blood.2021014901
PubMed Identifier: 35714312
Publication URI: http://europepmc.org/abstract/MED/35714312
Type: Journal Article/Review
Volume: 141
Parent Publication: Blood
Issue: 2
ISSN: 0006-4971